HRP20191513T1 - Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja - Google Patents

Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja Download PDF

Info

Publication number
HRP20191513T1
HRP20191513T1 HRP20191513T HRP20191513T1 HR P20191513 T1 HRP20191513 T1 HR P20191513T1 HR P20191513 T HRP20191513 T HR P20191513T HR P20191513 T1 HRP20191513 T1 HR P20191513T1
Authority
HR
Croatia
Prior art keywords
unsubstituted
substituted
carboaryl
aliphatic
independently selected
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Claude Michel Wischik
Dominic Venay Harbaran
Gernot Riedel
Serena Deiana
Elizabeth Anne Goatman
Damon Jude Wischik
Alison Dorothy Murray
Roger Todd Staff
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of HRP20191513T1 publication Critical patent/HRP20191513T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20191513 2007-06-19 2008-06-17 Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja HRP20191513T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment
EP08762390.6A EP2167095B1 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (1)

Publication Number Publication Date
HRP20191513T1 true HRP20191513T1 (hr) 2019-11-29

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191513 HRP20191513T1 (hr) 2007-06-19 2008-06-17 Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007008550D1 (de) 2006-03-29 2010-09-30 Wista Lab Ltd 3,7-diamino-10h-phenothiazinsalze und ihre verwendung
MY161656A (en) * 2007-10-03 2017-04-28 Wista Lab Ltd Therapeutic use of diaminophenothiazines
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
RS55237B1 (sr) 2011-02-11 2017-02-28 Wis Ta Laboratories Ltd Fenotiazin diaminijum soli i njihova primena
PL3686181T3 (pl) * 2013-01-30 2024-11-04 Ecolab Usa Inc. Zmiatacze siarkowodoru
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
CA2976776C (en) 2015-02-17 2023-06-20 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
KR102475825B1 (ko) * 2016-07-25 2022-12-08 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
EP4364801B1 (en) * 2018-07-26 2025-11-12 TauRx Therapeutics Management Ltd. Optimised dosage of diaminophenothiazines in populations
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Lab Ltd TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2004087160A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
EP2322517B1 (en) * 2004-09-23 2019-04-24 WisTa Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
AU2007231126B2 (en) 2006-03-29 2012-11-01 TauRx Therapeutics Management Ltd Inhibitors of protein aggregation
EP2853293B1 (en) 2006-03-29 2017-11-22 WisTa Laboratories Ltd. Thioninium compounds and their use
DE602007008550D1 (de) * 2006-03-29 2010-09-30 Wista Lab Ltd 3,7-diamino-10h-phenothiazinsalze und ihre verwendung
US7956183B2 (en) 2006-07-11 2011-06-07 Wista Laboratories Ltd. Methods of synthesis and/or purification of diaminophenothiazinium compounds

Also Published As

Publication number Publication date
SI2167095T1 (sl) 2019-09-30
PT2167095T (pt) 2019-08-06
WO2008155533A2 (en) 2008-12-24
AU2008265045B2 (en) 2014-02-27
BRPI0813670A2 (pt) 2014-12-30
AU2008265045A1 (en) 2008-12-24
US9211294B2 (en) 2015-12-15
ES2739546T3 (es) 2020-01-31
DK2167095T3 (da) 2019-07-29
EP2167095B1 (en) 2019-05-29
HUE045460T2 (hu) 2019-12-30
CA2690746A1 (en) 2008-12-24
WO2008155533A3 (en) 2009-02-19
CA2690746C (en) 2018-01-02
PL2167095T3 (pl) 2019-11-29
JP5725605B2 (ja) 2015-05-27
MY177001A (en) 2020-09-01
CN101820884A (zh) 2010-09-01
US20100184752A1 (en) 2010-07-22
JP2010530403A (ja) 2010-09-09
EP2167095A2 (en) 2010-03-31
CN101820884B (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
HRP20191513T1 (hr) Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja
SI2004155T1 (en) Protein aggregation inhibitors
CN101801942B (zh) 杂环化合物和作为抗癌剂的用途
ES2701089T3 (es) Uso terapéutico de las diaminofenotiazinas
WO2018075993A1 (en) Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors
CN103796654B (zh) 氘富集化4-羟基-5-甲氧基-n,1-二甲基-2-氧代-n-[(4-三氟-甲基)苯基]-1,2-二氢喹啉-3-甲酰胺
EP3684772B1 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
RU2017145692A (ru) Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи
ES2632471T3 (es) Novedosa sal de abexinostat, forma cristalina asociada, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
JP2010530403A5 (enExample)
EP2586780A4 (en) 2-ARYL-IMIDAZO- [1,2-A] -PYRIDINE-3-ACETAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
Su et al. The development of bis (hydroxymethyl) pyrrole analogs as bifunctional DNA cross-linking agents and their chemotherapeutic potential
HRP20220446T1 (hr) Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma)
WO2003062240A1 (de) Pteridinderivate, verfahren zu deren herstellung und ihre verwendung
HRP20181027T1 (hr) Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a
JP2002532503A5 (enExample)
JP2014514288A5 (enExample)
JP5733839B2 (ja) 神経変性疾患治療薬
Basavarajaiah et al. Pharmacological Activities of Some 5-Substituted-3-phenyl-Nβ-(substituted-2-oxo-2H-pyrano [2, 3-b] quinoline-3-carbonyl)-1H-indole-2-carboxyhydrazides
ES3012496T3 (en) Synthesis of a thiosulfonic acid by a step of periodate mediated oxidative coupling of a thiosulfonic acid with an aniline
ES2847229T3 (es) Compuestos intermedios utilizables en la síntesis de (-)-huperzina y proceso para obtener uno de estos compuestos intermedios
PE20250745A1 (es) Polimorfos cristalinos de (s)-2-etil-8-metil-1-tia-4,8-diazaspiro[4.5]decan-3-ona como agonista del receptor muscarinico de acetilcolina
KR20080056221A (ko) 베타 아밀로이드 응집의 나프틸 유도체 억제제
WO2016187377A1 (en) Compounds and methods for modulating serotonin receptors in the periphery
WO2017180723A1 (en) Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use